- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Multicentre
- Study aim: To describe the incidence and outcomes of COVID-19 among immunocompromised patients receiving tixagevimab/cilgavimab as preexposure prophylaxis during the Omicron wave in France
- Number of participants enrolled: 1112
- Study enrolling from to
- Study includes follow-up for 2 months
Study Data
- Adults
- Fragile population
- Immunocompromised host
- Hospital wide
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Monoclonal antibodies
- Tixagevimab/Cilgavimab
External Links
Other information
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to